HHS Selects First Drugs For Medicare Drug Price Negotiation
Portfolio Pulse from Benzinga Newsdesk
The Biden administration has selected the first 10 drugs for Medicare price negotiations, aiming to make prescription drugs more affordable for older Americans. The list of drugs includes those produced by companies such as AbbVie (ABBV), Amgen (AMGN), AstraZeneca (AZN), Bristol-Myers Squibb (BMY), Johnson & Johnson (JNJ), Merck (MRK), and Novartis (NVS).
August 29, 2023 | 11:42 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
AbbVie's drug is included in the Medicare price negotiations, which could potentially affect its revenue.
The inclusion of AbbVie's drug in the Medicare price negotiations could lead to a decrease in the price of the drug, potentially affecting the company's revenue and profitability.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 85
NEGATIVE IMPACT
Amgen's drug is included in the Medicare price negotiations, which could potentially affect its revenue.
The inclusion of Amgen's drug in the Medicare price negotiations could lead to a decrease in the price of the drug, potentially affecting the company's revenue and profitability.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 85
NEGATIVE IMPACT
AstraZeneca's drug is included in the Medicare price negotiations, which could potentially affect its revenue.
The inclusion of AstraZeneca's drug in the Medicare price negotiations could lead to a decrease in the price of the drug, potentially affecting the company's revenue and profitability.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 85
NEGATIVE IMPACT
Bristol-Myers Squibb's drug is included in the Medicare price negotiations, which could potentially affect its revenue.
The inclusion of Bristol-Myers Squibb's drug in the Medicare price negotiations could lead to a decrease in the price of the drug, potentially affecting the company's revenue and profitability.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 85
NEGATIVE IMPACT
Johnson & Johnson's drug is included in the Medicare price negotiations, which could potentially affect its revenue.
The inclusion of Johnson & Johnson's drug in the Medicare price negotiations could lead to a decrease in the price of the drug, potentially affecting the company's revenue and profitability.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 85
NEGATIVE IMPACT
Merck's drug is included in the Medicare price negotiations, which could potentially affect its revenue.
The inclusion of Merck's drug in the Medicare price negotiations could lead to a decrease in the price of the drug, potentially affecting the company's revenue and profitability.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 85
NEGATIVE IMPACT
Novartis's drug is included in the Medicare price negotiations, which could potentially affect its revenue.
The inclusion of Novartis's drug in the Medicare price negotiations could lead to a decrease in the price of the drug, potentially affecting the company's revenue and profitability.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 85